clinical trial · NCT05923541
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
Hematologic MalignanciesRD13-02 cell infusion
brief summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.
started
Jun 26, 2023
primary completion
Aug 31, 2024
completion
Aug 31, 2024
last updated
Nov 22, 2024
official title
Clinical Study on Efficacy, Safety and Cytopharmacokinetics of RD13-02 Cell Injection in the Treatment of Patients With Recurrent or Refractory CD7-positive Hematologic Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol